Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Protagonist Therapeutics Inc (NASDAQ: PTGX) closed the day trading at $53.01 down -3.23% from the previous closing price of $54.78. In other words, the price has decreased by -$3.23 from its previous closing price. On the day, 1.28 million shares were traded. PTGX stock price reached its highest trading level at $54.25 during the session, while it also had its lowest trading level at $52.26.
Ratios:
For a better understanding of PTGX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.80. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when WILLIAM D WADDILL bought 4,000 shares for $54.78 per share.
MOLINA ARTURO MD sold 30,514 shares of PTGX for $1,700,850 on Mar 13 ’25. The Chief Medical Officer now owns 83,892 shares after completing the transaction at $55.74 per share. On Mar 12 ’25, another insider, Ali Asif, who serves as the Chief Financial Officer of the company, sold 24,903 shares for $58.73 each. As a result, the insider received 1,462,553 and left with 62,821 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3253981696 and an Enterprise Value of 2845934080. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.49 while its Price-to-Book (P/B) ratio in mrq is 4.79. Its current Enterprise Value per Revenue stands at 6.551 whereas that against EBITDA is 11.219.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.23, which has changed by 0.8393477 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is 32.54%, while the 200-Day Moving Average is calculated to be 31.19%.
Shares Statistics:
Over the past 3-months, PTGX traded about 883.57K shares per day on average, while over the past 10 days, PTGX traded about 1981820 shares per day. A total of 61.04M shares are outstanding, with a floating share count of 57.87M. Insiders hold about 5.72% of the company’s shares, while institutions hold 100.46% stake in the company. Shares short for PTGX as of 1740700800 were 4865114 with a Short Ratio of 5.51, compared to 1738281600 on 3793117. Therefore, it implies a Short% of Shares Outstanding of 4865114 and a Short% of Float of 8.0299996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
